Heterogeneous mechanisms of primary and acquired resistance to third-generation EGFR inhibitors.
about
Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung CancerTriplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790M in vivo.Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance.Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapyLiquid biopsies in lung cancer-time to implement research technologies in routine care?Overcoming resistance to EGFR tyrosine kinase inhibitors in lung cancer, focusing on non-T790M mechanisms.Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer.Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors.Molecular mechanisms of therapy resistance in solid tumors: chasing "moving" targets.Epithelial-to-mesenchymal transition and its role in EGFR-mutant lung adenocarcinoma and idiopathic pulmonary fibrosis.Osimertinib: A Review in T790M-Positive Advanced Non-Small Cell Lung Cancer.Lung cancer as a paradigm for precision oncology in solid tumours.Conventional real-time PCR-based detection of T790M using tumor tissue or blood in patients with EGFR TKI-resistant NSCLC.Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines.Mechanisms of resistance to irreversible epidermal growth factor receptor tyrosine kinase inhibitors and therapeutic strategies in non-small cell lung cancer.MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib.Optimizing outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when?Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation.Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC).Heterogeneity-based, multiple mechanisms in the resistance to osimertinib (AZD9291): A case report.Cis-oriented solvent-front EGFR G796S mutation in tissue and ctDNA in a patient progressing on osimertinib: a case report and review of the literature.EGFR-TKIs resistance via EGFR-independent signaling pathways.Third generation EGFR TKIs: current data and future directions.[Mechanisms of Resistance to the Third-generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer].Mechanisms of Resistance to Target Therapies in Non-small Cell Lung Cancer.NIPS, a 3D network-integrated predictor of deleterious protein SAPs, and its application in cancer prognosis.Novel approaches against epidermal growth factor receptor tyrosine kinase inhibitor resistance.PanDrugs: a novel method to prioritize anticancer drug treatments according to individual genomic data.Resistance to epidermal growth factor receptor tyrosine kinase inhibitors, T790M, and clinical trials.The continued EGFR-TKI with cytotoxic chemotherapy at progression-poison or medicine?Mitochondrial metabolism and cancerOvercoming EGFR-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors
P2860
Q33740707-F5E4E787-D863-4A9C-8E40-49DD2F0A7F6EQ33787355-68470B08-662B-4239-9BD7-6C30B6BF1DE2Q34550460-5321597E-AD7F-4557-88CA-38903E6AB413Q38598893-B6543F63-48C5-496D-91D4-B57AA38542D0Q38649535-7829E6A1-0C86-45C4-96B5-3D33C9DEF961Q38682189-4167724B-9DA3-4861-A266-22F2DF06FE69Q38790929-5FF5A548-B12E-4315-888B-0A4A3474AC08Q38988061-4E1573D3-99E3-4550-9108-5BE9F68E5895Q39172297-83A30B37-85CC-4017-877E-4D682D2990BBQ39415339-5EB7BE61-3040-4692-862C-20B180B01C8DQ39436392-12F9A46F-0625-4C75-BECE-9B47341C7C27Q39449763-A2B5839C-82D9-441B-9FC4-78A6EDA2FDF0Q40489387-8F228B07-D136-4103-95F0-8E2F815ED0A2Q47141830-77D9E680-812F-4CA7-BC19-511257510CD7Q47146662-4BF5118A-28D4-491F-9A8C-F405E26C4E6EQ47547443-D3725593-051A-4FB8-8328-B7B876FD8296Q47730834-E6B7E240-B1A2-4436-AAC3-E21F1AD0A87CQ47814631-A9CF13A5-AEC9-4EE8-8C5A-87275DE92319Q48091386-B788AA25-9D9C-4671-9CA3-84BD447E9340Q48091584-8B4CFB81-20F6-414D-93AD-A69FFB8B5557Q49643911-EAD3A1A0-7E1C-4C32-914F-164DE8461E2EQ49887890-02F814A1-8360-4BC7-BA37-A47651EDFDD1Q49887956-E902C40C-B20D-4DB6-91CC-D4CA3B52AA1EQ51741619-2DE69831-D8BC-4F00-9C7D-B0DE6C669EAAQ52312436-0CFF1315-F10B-495E-BEDC-615E4FFD2956Q52584601-C6821335-CD40-4F5E-B89C-4732D8716852Q52597593-6B6B0D6D-E400-4EC3-85C9-9B580FE94105Q55017642-836CEB68-9D53-44D2-90F5-6316315B902CQ55191884-21D450B1-CED3-4F71-A925-2C51594A87EBQ55223055-F5A0B051-BA10-489A-AAFC-FD0AA5F095B3Q57842307-D5852083-ABA8-4D8D-B23B-1A6BAC139547Q58599659-BCC9F103-6617-4567-8773-2A712C205802
P2860
Heterogeneous mechanisms of primary and acquired resistance to third-generation EGFR inhibitors.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Heterogeneous mechanisms of pr ...... rd-generation EGFR inhibitors.
@en
Heterogeneous mechanisms of pr ...... rd-generation EGFR inhibitors.
@nl
type
label
Heterogeneous mechanisms of pr ...... rd-generation EGFR inhibitors.
@en
Heterogeneous mechanisms of pr ...... rd-generation EGFR inhibitors.
@nl
prefLabel
Heterogeneous mechanisms of pr ...... rd-generation EGFR inhibitors.
@en
Heterogeneous mechanisms of pr ...... rd-generation EGFR inhibitors.
@nl
P2093
P50
P1476
Heterogeneous mechanisms of pr ...... rd-generation EGFR inhibitors.
@en
P2093
Alexandra Florin
Andreas Scheel
Carina Heydt
Christian Becker
Christian Müller
Dennis Plenker
Helen Pasternack
Hongbin Ji
Ilona Dahmen
Jana Fassunke
P356
10.1158/1078-0432.CCR-15-1915
P407
P50
P577
2016-06-01T00:00:00Z